Search

Your search keyword '"Heinzlef, Olivier"' showing total 262 results
Start Over Author "Heinzlef, Olivier"
262 results on '"Heinzlef, Olivier"'

3. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study

Author

Wilson, Sarah, Calocer, Floriane, Rollot, Fabien, Fauvernier, Mathieu, Remontet, Laurent, Tron, Laure, Vukusic, Sandra, Le Page, Emmanuelle, Debouverie, Marc, Ciron, Jonathan, Ruet, Aurélie, De Sèze, Jérôme, Zephir, Hélène, Moreau, Thibault, Lebrun-Frénay, Christine, Laplaud, David-Axel, Clavelou, Pierre, Labauge, Pierre, Berger, Eric, Pelletier, Jean, Heinzlef, Olivier, Thouvenot, Eric, Camdessanché, Jean Philippe, Leray, Emmanuelle, Dejardin, Olivier, and Defer, Gilles

Published
2023
Full Text
View/download PDF

4. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Debouverie, Marc, Le Page, Emmanuelle, Ciron, Jonathan, De Seze, Jerome, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanche, Jean-Philippe, Maurousset, Aude, Moulin, Solène, Ben, Nasr Haifa, Boulos, Dalia Dimitri, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Rabilloud, Muriel, Subtil, Fabien, and Vukusic, Sandra

Published
2022
Full Text
View/download PDF

7. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B, Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C, Rasmussen, Peter V, Jensen, Michael B, Frederiksen, Jette L, Bramow, Stephan, Mathiesen, Henrik K, Schreiber, Karen I, Horakova, Dana, Havrdova, Eva K, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D, Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean-Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A, Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, and Magyari, Melinda

Published
2021
Full Text
View/download PDF

8. Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

Author

Mathais, Sophie, Moisset, Xavier, Pereira, Bruno, Taithe, Frédéric, Ciron, Jonathan, Labauge, Pierre, Dulau, Cécile, Laplaud, David, De Seze, Jérôme, Pelletier, Jean, Berger, Eric, Lebrun-Frenay, Christine, Castelnovo, Giovanni, Edan, Gilles, Defer, Gilles, Vermersch, Patrick, Bourre, Bertrand, Camdessanche, Jean-Philippe, Magy, Laurent, Guennoc, Anne-Marie, Mathey, Guillaume, Moreau, Thibault, Gout, Olivier, Heinzlef, Olivier, Maillart, Elisabeth, Vukusic, Sandra, and Clavelou, Pierre

Published
2021
Full Text
View/download PDF

10. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022

Author

Jeantin, Lina, primary, Januel, Edouard, additional, Labauge, Pierre, additional, Maillart, Elisabeth, additional, de Seze, Jérôme, additional, Zéphir, Hélène, additional, Pelletier, Jean, additional, Kerschen, Philippe, additional, Biotti, Damien, additional, Heinzlef, Olivier, additional, Guilloton, Laurent, additional, Bensa, Caroline, additional, Théaudin, Marie, additional, Vukusic, Sandra, additional, Casez, Olivier, additional, Maurousset, Aude, additional, Laplaud, David, additional, Berger, Eric, additional, Lebrun-Frenay, Christine, additional, Bourre, Bertrand, additional, Branger, Pierre, additional, Stankoff, Bruno, additional, Clavelou, Pierre, additional, Thouvenot, Eric, additional, Manchon, Eric, additional, Moreau, Thibault, additional, Sellal, François, additional, Zedet, Mickaël, additional, Papeix, Caroline, additional, and Louapre, Céline, additional

Published
2024
Full Text
View/download PDF

12. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Published
2021
Full Text
View/download PDF

13. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Kerbrat, Anne, Le Page, Emmanuelle, Bigaut, Kevin, Mathey, Guillaume, Michel, Laure, Ciron, Jonathan, Ruet, Aurelie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al-Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanché, Jean-Philippe, Doghri, Inès, Moulin, Solène, Ben-Nasr, Haifa, Labeyrie, Céline, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Manchon, Eric, Lapergue, Bertrand, Wiertlewski, Sandrine, De Sèze, Jérôme, Vukusic, Sandra, and Laplaud, David Axel

Abstract

IMPORTANCE: Understanding the association between clinically defined relapses and radiological activity in multiple sclerosis (MS) is essential for patient treatment and therapeutic development. OBJECTIVE: To investigate clinical events identified as relapses but not associated with new T2 lesions or gadolinium-enhanced T1 lesions on brain and spinal cord magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: This multicenter observational cohort study was conducted between January 2015 and June 2023. Data were extracted on June 8, 2023, from the French MS registry. All clinical events reported as relapses in patients with relapsing-remitting MS were included if brain and spinal cord MRI was performed within 12 and 24 months before the event, respectively, and 50 days thereafter with gadolinium injection. EXPOSURES: Events were classified as relapses with active MRI (RAM) if a new T2 lesion or gadolinium-enhanced T1 lesion appeared on brain or spinal cord MRI or as acute clinical events with stable MRI (ACES) otherwise. MAIN OUTCOMES AND MEASURES: Factors associated with ACES were investigated; patients with ACES and RAM were compared regarding Expanded Disability Status Scale (EDSS) course, relapse rate, confirmed disability accrual (CDA), relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and transition to secondary progressive (SP) MS, and ACES and RAM rates under each disease-modifying therapy (DMT) were estimated. RESULTS: Among 31 885 clinical events, 637 in 608 patients (493 [77.4%] female; mean [SD] age, 35.8 [10.7] years) were included. ACES accounted for 166 (26.1%) events and were more likely in patients receiving highly effective DMTs, those with longer disease duration (odds ratio [OR], 1.04; 95% CI, 1.01-1.07), or those presenting with fatigue (OR, 2.14; 95% CI, 1.15-3.96). ACES were associated with significant EDSS score increases, lower than those found for RAM. Before the index event, patients with ACES experienced significantly higher rates of relapse (relative rate [RR], 1.21; 95% CI, 1.01-1.46), CDA (hazard ratio [HR], 1.54; 95% CI, 1.13-2.11), and RAW (HR, 1.72; 95% CI, 1.20-2.45). Patients with ACES were at significantly greater risk of SP transition (HR, 2.58; 95% CI, 1.02-6.51). Although RAM rate decreased with DMTs according to their expected efficacy, ACES rate was stable across DMTs. CONCLUSIONS AND RELEVANCE: The findings in this study introduce the concept of ACES in MS, which accounted for one-fourth of clinical events identified as relapses.

Published
2024
Full Text
View/download PDF

14. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality

Author

Rollot, Fabien, primary, Uhry, Zoé, additional, Dantony, Emmanuelle, additional, Vukusic, Sandra, additional, Debouverie, Marc, additional, Le Page, Emmanuelle, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, De Sèze, Jérome, additional, Zéphir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun-Frenay, Christine, additional, Moreau, Thibault, additional, Laplaud, David A., additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Camdessanche, Jean-Philippe, additional, Fauvernier, Mathieu, additional, Remontet, Laurent, additional, and Leray, Emmanuelle, additional

Published
2023
Full Text
View/download PDF

16. Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care

Author

Gay, Marie Claire, primary, Cassedanne, Fanny, additional, Barbot, Frederic, additional, Vaugier, Isabelle, additional, Thomas, Sarah, additional, Manchon, Eric, additional, Bensmail, Djamel, additional, Blanchere, Marie, additional, and Heinzlef, Olivier, additional

Published
2023
Full Text
View/download PDF

17. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Author

Jouvenot, Guillaume, Courbon, Guilhem, Lefort, Mathilde, Rollot, Fabien, Casey, Romain, Le Page, Emmanuelle, Michel, Laure, Edan, Gilles, de Seze, Jérome, Kremer, Laurent, Bigaut, Kevin, Vukusic, Sandra, Mathey, Guillaume, Ciron, Jonathan, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al-Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanché, Jean-Philippe, Doghri, Ines, Moulin, Solène, Ben-Nasr, Haifa, Labeyrie, Céline, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Collongues, Nicolas, and Kerbrat, Anne

Abstract

IMPORTANCE: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity. OBJECTIVE: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patients in the database, data were extracted for 1857 patients 50 years and older with relapsing-remitting MS treated by HET and with no relapse or magnetic resonance imaging activity for at least 2 years. After verification of the medical records, 1620 patients were classified as having discontinued HET or having remained taking treatment and were matched 1:1 using a dynamic propensity score (including age, sex, disease phenotype, disability, treatment of interest, and time since last inflammatory activity). Patients were included from February 2008 to November 2021, with a mean (SD) follow-up of 5.1 (2.9) years. Data were extracted in June 2022. EXPOSURES: Natalizumab, fingolimod, rituximab, and ocrelizumab. MAIN OUTCOMES AND MEASURES: Time to first relapse. RESULTS: Of 1620 included patients, 1175 (72.5%) were female, and the mean (SD) age was 54.7 (4.8) years. Among the 1452 in the HET continuation group and 168 in the HET discontinuation group, 154 patients in each group were matched using propensity scores (mean [SD] age, 57.7 [5.5] years; mean [SD] delay since the last inflammatory activity, 5.6 [3.8] years; mean [SD] follow-up duration after propensity score matching, 2.5 [2.1] years). Time to first relapse was significantly reduced in the HET discontinuation group compared with the HET continuation group (hazard ratio, 4.1; 95% CI, 2.0-8.5; P < .001) but differed between HETs, with a hazard ratio of 7.2 (95% CI, 2.1-24.5; P = .001) for natalizumab, 4.5 (95% CI, 1.3-15.5; P = .02) for fingolimod, and 1.1 (95% CI, 0.3-4.8; P = .85) for anti-CD20 therapy. CONCLUSION AND RELEVANCE: As in younger patients, in patients 50 years and older with nonactive MS, the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking (natalizumab and fingolimod). There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 therapy). This result may inform decisions about stopping HETs in clinical practice.

Published
2024
Full Text
View/download PDF

18. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance

Author

Abbas, Firas, Abdelmoumni, Abdelhakim, Hilliquin, Pascal, Requeda, Elisabeth, Adoue, Daniel, Brassat, David, Agard, Christian, Masseau, Agathe, Aladjidi, Nathalie, Clet, Johanna, Fernandes, Helder, Lemasson, Gwendal, Perel, Yves, Raymond, Isabelle, Richer, Olivier, Vital, Anne, Allain-Launay, Emma, Bru, Marie, Nicolino, Marc, Thomas, Caroline, Altman, Jean-Jacques, Amsallem, Daniel, Aras, Nazmiye, Boukari, Latifato, Dubrel, Marie, Fain, Olivier, Letellier, Edouard, Lucidarme, Nadine, Mekinian, Arsène, Morin, Anne-Sophie, Stirnemann, Jérôme, Atlan, Catherine, Audry, Dominique, Augustin, Jérôme, Bakir, Redouane, Bartolucci, Pablo, Chevalier, Xavier, Godeau, Bertrand, Guillaud, Constance, Khellaf, Mehdi, Limal, Nicolas, Lousteau, Valentine, Mahevas, Matthieu, Méliksetyan, Gayane, Michel, Marc, Roumier, Mathilde, Bayart, Sophie, Bonnet, Fabrice, Decaux, Olivier, Bekherraz, Amine, Brihaye, Benoit, Dachez, Roger, Daugas, Eric, Hayem, Gilles, Meyer, Olivier, Papo, Thomas, Pasqualoni, Elisa, Sacre, Karim, Travert, Florence, Bellon, Hélène, Beltrand, Jacques, Lefrere, François, Simon, Albane, Benhamou, Pierre-Yves, Benveniste, Olivier, Bolgert, Francis, Costedoat-Chalumeau, Nathalie, De Paz, Raphael, Demeret, Sophie, Fautrel, Bruno, Jacqueminet, Sophie, Louapre, Céline, Maillart, Elizabeth, Morel, Nathalie, Papeix, Caroline, Rigabert, Julie, Bensaid, Philippe, Berger, Claire, Berquin, Patrick, Le Moing, Anne-Gaëlle, Berroir, Stéphane, Besson, Gérard, Boutte, Célia, Casez, Olivier, Bonnotte, Bernard, Audia, Sylvain, Bossu-Estour, Cécile, Bourgarit, Anne, Dupuy, Alain, Keshmandt, Homa, Bourre, Bertrand, Brac, Aude, Perrin, Agnès, Pondarré, Corinne, Villar-Fimbel, Sylvie, Bruckert, Isabelle, Cosson, Anne, Magy-Bertrand, Nadine, Tisserand, Guillaume, Camu, William, Carlander, Bertrand, Morales, Raul Juntas, Cances, Claude, Pasquet, Marlene, Castilla Lievre, Maria Angela, Chabroux, Stephanie, Charif, Mamoud, Chatelus, Emmanuel, Sibilia, Jean, Chevrant-Breton, Jacqueline, Clavel, Sylvaine, Bille-Turc, Françoise, Cohen, Jacques, Courcoux, Marie France, Leverger, Guy, Machet, Laurent, Cuisset, Jean-Marie, Cony-Makhoul, Pascale, Darsy, Paul, Favre, Sandrine, Giraud, Pierrick, Leitenschenck, Laurence, Monteiro, Irène, Morati, Chafika, DeSeze, Jérôme, Dinulescu, Monica, Dhaoui, Taher, Dommange-Romero, Florence, Drevard, Elisabeth, Dupuis, Clémentine, Dumuis, Marie-Laure, Durand, Jean-Marc, Farad, Samia, Lecomte, Pierre, Pierre, Peggy, Fouyssac, Fanny, Gaudin, Philippe, Gautier, Alain, Gellen-Dautremer, Justine, Jarrin, Irène, Richette, Pascal, Georget, Emilie, Gras, Pierre, Moreau, Thibault, Giraud, Eric, Hacini, Maya, Mayer, Anne, Guillaumat, Cécile, Guillaume, Séverine, Guitton, Corinne, Kone-Paut, Isabelle, Marsaud, Céline, Rossi, Linda, Guyot, Marie-Hélène, Hassler, Patrick, Heimfert, Claude, Heinzlef, Olivier, Hillion, Brigitte, Hocquelet, Catherine, Husson, Helene, Ichai, Pierre, Jeziorski, Eric, Deslandre, Chantal Job, Le Guern, Véronique, Kamenov, Kamen, Kerlan, Véronique, Lemoine, Philippe, Misery, Laurent, Pan-Petesch, Brigitte, Krivitzky, Alain, Labauge, Pierre, Rodier, Michel, Lacade, Chadi, Razafimahefa, Berthe, Lachgar, Karim, Larmarau, Marie-Pierre, Leblanc, Thierry, Lebrun-Frenay, Christine, Lefèbvre, Patrick, Lejoyeux, Philippe, Leske, Charles, Ly, Kim, Magy, Laurent, Mansuy, Sylvie, Marechaud, Richard, Martin Negrier, Marie-Laure, Sole, Guilhem, Maupetit, Jean, Mazingue, Françoise, Mochon, Stéphanie, Moktar, Blidi, Morcamp, Donald, Morlet-Barla, Nathalie, Nicolas, Guillaume, Pautot, Vivien, Pellier, Isabelle, Verret, Jean-Luc, Outteryck, Olivier, Vermersch, Patrick, Pallot-Prades, Beatrice, Paquet, Jean Michel, Puechal, Xavier, Sortais, Annie, Pelletier, Jean, Rico, Audrey, Pez, Dominique, Stankoff, Bruno, Quittet, Philippe, Rémy, Claude, Roba, Eléna, Rosario, Hélène, Roudaut, Nathalie, Sonnet, Emmanuel, Ruel, Michel, Sebban, Samuel, Schaepelynck, Pauline, Simonin, Marie-Jeanne, Vial, Christophe, Viallard, Jean-Francois, Ladedan, Isabelle, Zenone, Thierry, Grimaldi-Bensouda, Lamiae, Rossignol, Michel, Koné-Paut, Isabelle, Courcoux, Marie-France, Viallard, Jean-François, Bourgault-Villada, Isabelle, Breart, Gerard, and Abenhaim, Lucien

Published
2017
Full Text
View/download PDF

19. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.

Author

Benallegue, Nail, Rollot, Fabien, Wiertlewski, Sandrine, Casey, Romain, Debouverie, Marc, Kerbrat, Anne, De Seze, Jérôme, Ciron, Jonathan, Ruet, Aurelie, Labauge, Pierre, Maillart, Elisabeth, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, and Heinzlef, Olivier

Published
2024
Full Text
View/download PDF

20. Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care.

Author

Gay, Marie Claire, Cassedanne, Fanny, Barbot, Frederic, Vaugier, Isabelle, Thomas, Sarah, Manchon, Eric, Bensmail, Djamel, Blanchere, Marie, and Heinzlef, Olivier

Subjects
BEHAVIOR therapy, FATIGUE (Physiology), COGNITIVE therapy, MULTIPLE sclerosis, CANCER fatigue, DISEASE relapse, ANXIETY disorders, GROUP psychotherapy
Published
2024
Full Text
View/download PDF

23. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study

Author

Peyro Saint Paul, Laure, Creveuil, Christian, Heinzlef, Olivier, De Seze, Jerome, Vermersch, Patrick, Castelnovo, Giovanni, Cabre, Philippe, Debouverie, Marc, Brochet, Bruno, Dupuy, Benoit, Lebiez, Pierre, Sartori, Éric, Clavelou, Pierre, Brassat, David, Lebrun-Frenay, Christine, Daplaud, David, Pelletier, Jean, Coman, Irène, Hautecoeur, Patrick, Tourbah, Ayman, and Defer, Gilles

Published
2016
Full Text
View/download PDF

24. Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France

Author

Heinzlef, Olivier, Molinier, Guillaume, van Hille, Benoît, Radoszycki, Lise, Dourgnon, Paul, and Longin, Juliette

Abstract

Background: People with chronic diseases in France frequently incur out-of-pocket expenses (OOPE) related to their medical care. Objective: The objective of this study was to evaluate OOPE incurred by people with multiple sclerosis (MS) with respect to direct non-medical and medical expenditure. Methods: Data were collected through a web-based survey using an online patient community platform (Carenity). The survey questionnaire contained 87 questions (numerical response or Likert scale) and took less than 30 min to complete. Participants rated their disability on a ten-point scale. Results: In total, 376 patients, with a mean age of 48.3 years (95% confidence interval [CI] 47.2–49.5), participated in the survey. Participants estimated that they spent an average of €127 each month on OOPE for their MS, principally on physician consultations (mean annual expenditure of €75 by 183 participants), non-physician consultations (€358 by 135 participants) and non-prescription medication (mean expense of €67 per pharmacy visit by 234 patients). In total, 77% of participants who needed adaptations to their home or vehicle because of their MS contributed to the cost. No obvious relationship between OOPE and self-rated disability was observed. A total of 61.4% of participants reported that they had to choose between spending money on MS care or on their family and social life. Conclusions: Most patients with MS incurred significant OOPE linked to consultations, non-prescription medications or home equipment and medical equipment. These outlays could lead to dilemmas when choosing between spending on MS care or family or social life.

Published
2024
Full Text
View/download PDF

25. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

Author

Laplaud, David-Axel, Casey, Romain, Barbin, Laetitia, Debouverie, Marc, De Sèze, Jérôme, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Lubetzki, Catherine, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Guennoc, Anne-Marie, Maubeuge, Nicolas, Labeyrie, Céline, Patry, Ivania, Nifle, Chantal, Casez, Olivier, Michel, Laure, Rollot, Fabien, Leray, Emmanuelle, Vukusic, Sandra, Foucher, Yohann, Fontaine, B., Marignier, R., Durand-Dubief, F., Mathey, G., Le Page, E., Peaureaux-Averseng, D., Ouallet, J.C., Ruet, A., Collongues, N., Hautecoeur, P., Zephir, H., Maillard, E., Cohen, M., Derache, N., Branger, P., Ayrignac, X., Carra-Dalliere, C., Fromont, A., Chamard-Witkowski, L., Taithe, F., Moisset, X., Audoin, B., Rico-Lamy, A., Castelnovo, G., Giannesini, C., Fagniez, O., Bensa, C., Gueguen, A., Kasonde, I. Tabellah, De Vilmarest, A., Montcuquet, A., Vaillants, M., Beltran, S., Creange, A., Ayache, S., Abdellaoui, M., Pottier, C., Slesari, I., Deburghraeve, V., Neau, J.P., Servan, J., Pico, F., Henry, C., and Hankiewicz, K.

Published
2019
Full Text
View/download PDF

26. Post-Covid-19 Acute Disseminated Encephalomyelitis (ADEM) in a 27-year-old girl: Case Report

Author

HEINZLEF Olivier, YAÏCHE Hugo, AWIDINA-AMA Awissoba, SORO Donissongui, and AGBA Léhleng

Abstract

Acute disseminated encephalomyelitis (ADEM) is a monophasic, multifocal, demyelinating, autoimmune disease that affects the central nervous system (CNS). It usually occurs after a systemic infection, usually viral, including certain coronavirus infections. A 27-year-old girl presented with complaints of left interscapular pain, paresthesias and weakness in the ipsilateral upper limb. These symptoms followed paresthesias on the fingertips of her right hand the day before her admission. she was treated two weeks earlier for pneumonia with COVID-19. Her clinical pattern resulted in a moderate weakness of the left limbs associated with tactil and algic hypoesthesia in the lower left limb ascending until the C4 level in the left side. Magnetic resonance imaging (MRI) of the brain and spinal cord showed diffuse spontaneous hypersignals on fluid-attenuated inversion recovery (FLAIR) images at the cerebral level and on T2-weighted images at the spinal level. These imaging lesions coupled with the medical history of a recent COVID-19 infection led to the diagnosis of acute disseminated encephalomyelitis (ADEM) post covid-19. The clinical condition improved rapidly with intravenous (IV) corticosteroid therapy and IV immunoglobulin combined with physiotherapy. ADEM is a demyelinating autoimmune disease which is increasingly reported during this current corona virus pandemic.

Published
2022
Full Text
View/download PDF

27. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

Author

Papeix, Caroline, Castelnovo, Giovanni, Leray, Emmanuelle, Coustans, Marc, Levy, Pierre, Visy, Jean-Marc, Kobelt, Gisela, Lamy, Fabienne, Allaf, Bashar, Heintzmann, François, Chouette, Isabelle, Raponi, Eric, Durand, Barbara, Grevat, Emmanuelle, Kamar, Driss, Debouverie, Marc, Lebrun-Frenay, Christine, Abdelmoumni, Abdelhakim, Al Aloucy, Mouhmmad Jamal, Al Khedr, Abdullatif, Al Najjar Carpentier, Amer, Alonzo, Bernard, Altarcha, Tony, Ananivi, Amevi, Androdias, Géraldine, Angibaud, Gilles, Artaud-Uriot, Marie-Sylvie, Audry-Chaboud, Dominique, Barre, Marie, Barres, Philippe, Benrabah, Rabah, Berger, Eric, Bergouignan, François-Xavier, Bernady, Patricia, Billy, Christophe, Blanchard, Christian, Bonnan, Mickaël, Borsotti, Jean-Paul, Bossu-van Nieuwenhuyse, Catherine, Bouffeteau, Jean-Claude, Bouillaguet, Sophie, Boukriche, Yassine, Boulesteix, Jean-Marc, Bourre, Bertrand, Brassat, David, Bredin, Alain, Brochet, Bruno, Brugeilles Baguelin, Helene, Camara, Ousmane, Camdessanche, Jean-Philippe, Camu, William, Carel, Christophe, Carlander, Bertrand, Casez, Olivier, Chanel-Soulier, Marie-Pierre, Chapuis, Stéphane, Cimpoesu, Mirella, Ciron, Jonathan, Clavelou, Pierre, Clerc, Christine, Colamarino, Renato, Couratier, Christophe, Courtois, Sylvie, Creange, Alain, Danielli, Antoine, de Broucker, Thomas, de Seze, Jérôme, Defer, Gilles, Delorme, Jérôme, Denis, Béatrice, Derouiche, Fayçal, Devos, Philippe, Deyrolle, Anne-Marie, Dib, Michel, Dib, Joseph, Diot, Eric, Doury, Emmanuelle, Dufourd-Delalande, Sophie, Dupel-Pottier, Corinne, Dussaux, Patrick, Edan, Gilles, Edouard, Thibault, Escaillas, Jean-Pierre, Ferriby, Didier, Fouillet, Nicolas, Fromager, Guillaume, Gaida-Rostane, Tsouria, Gaida, Philippe, Gal, Guillaume, Garrigues, Guillaume, Gayou-Joyeux, Annick, Gentil, Arnaud, Gerard, Philippe, Gere, Julien, Gignoux, Laurence, Girard, Philippe, Giraud, Pierric, Gouttard, Michel, Gras, Pierre, Guennoc, Anne Marie, Gugenheim, Michel, Guilloton, Laurent, Hadjout, Karim, Hautecoeur, Patrick, Hegbe, Yawo, Heinzlef, Olivier, Henry, Patrice, Herve, Yann, Hijazi, Jihad, Homeyer, Pascale, Huttin, Bernard, Ille, Olivier, Jager, Alain, Jomir, Laurentiu, Kardous, Nabil, Kerouanton, Agnès, Kpade, Comlan Paul, Kubler, Christophe, Labauge, Pierre, Lallement, François, Landragin, Nicolas, Laplaud, David Axel, Laribi, Henda, Lavernhe, Gilles, Le Biez, Pierre-Éric, Le Bras, Françoise, Le Coz, Patrick, Leche, Josette, Leder, Sara Julia, Legout, Alain, Levasseur, Michele, Lorenzi-Pernot, Alberta, Louchart, Pierre, Louillet, Fabien, Magy, Laurent, Maillard, Sophie, Maillart, Elisabeth, Maillet-Vioud, Marcel, Mallecourt-Emberger, Catherine, Manchon, Éric, Mania, Alexandre, Martinez-Almoyna, Laurent, Martinez, Mikel, Massengo, Serge, Maugin, Dominique, Medjbeur, Souraya, Meliksetyan, Gayané, Menassa, Michael, Meshaka-Dimitri-Boulos, Dalia, Mick, Gérard, Moreau, Thibault, Moulignier, Antoine, Mourand, Isabelle, Muller, Jean-Philippe, Neuschwander, Philippe, Nibbio, Argentino, Nifle, Chantal, Nkendjuo, Jean-Bertin, Nokam Talom, Ghislain, Ory, Sophie, Patry, Ivania, Pedespan, Bernard, Pelletier, Jean, Pencu, Delia-Gianina, Perrouty, Bruno, Peysson, Stéphane, Popa-Coman, Irène, Pouliquen, André, Prat, Christophe, Prundean, Adriana, Radji, Fataï, Rakotoharinandrasana, Haja Tiana, Razlog, Lilia, Remy, Philippe, Robin, Christophe, Rodier, Gilles, Romero, Jérôme, Roualdes, Brigitte, Rouhart, François, Ruggieri, Irene, Samad, Feras Abdul, Sarafiant, Irina, Schaeffer, Stephane, Schmidt, Nicolas, Schuermans, Philippe, Seiller, Nicolas, Soisson, Thierry, Sortais, Annie, Stankoff, Bruno, Stefanizzi-Debuc, Sabrina, Suchet, Laurent, Tardy, Jean, Taurin, Gregory, Thabuy, Florent, Theaudin, Marie, Tilikete-Froment, Caroline, Tourbah, Ayman, Tourniaire, Patricia, Trefouret, Sylvie, Vastene, Michel, Verdure, Pierre, Vermersch, Patrick, Viala, Frédérique, Videt-Gibou, Dorothée, Vidry, Elisabeth, Vukusic, Sandra, Wagner, Marc, Wattier, Valery, Zaenker, Christophe, Ziegler, François, Zola, Jean-Médard, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), and Collectif de recherche handicap, autonomie et société inclusive (CoRHASI)

Subjects
Quality of life, Disability, Neurology, Relapsing–remitting multiple sclerosis, Radiological markers, Disease-modifying treatment, Effectiveness, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Tolerability
Abstract

Online ahead of print; International audience; Introduction: It is important to confirm the effectiveness and tolerability of disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS) in real-world treatment settings. This prospective observational cohort study (VIRGILE) was performed at the request of the French health authorities. The primary objective was to evaluate the effectiveness of fingolimod 0.5 mg in reducing the annualised relapse rate (ARR) in patients with RRMS.Methods: Participating neurologists enrolled all adult patients with RRMS starting fingolimod treatment between 2014 and 2016, who were followed for 3 years. Follow-up consultations took place at the investigator's discretion. The primary outcome measure was the change in ARR at month 24 after fingolimod initiation. Relapses and adverse events were documented at each consultation; disability assessment (EDSS) and magnetic resonance imagery were performed at the investigator's discretion.Results: Of 1055 eligible patients, 633 patients were assessable at month 36; 405 (64.0%) were treated continuously with fingolimod for 3 years. The ARR decreased from 0.92 ± 0.92 at inclusion to 0.31 ± 0.51 at month 24, a significant reduction of 0.58 [95% CI - 0.51 to - 0.65] relapses/year (p < 0.001). Since starting fingolimod, 461 patients (60.9%) remained relapse-free at month 24 and 366 patients (55.5%) at month 36. In multivariate analysis, no previous disease-modifying treatment, number of relapses in the previous year and lower EDSS score at inclusion were associated with a greater on-treatment reduction in ARR. The mean EDSS score remained stable over the course of the study. Sixty-one out of 289 (21.1%) patients presented new radiological signs of disease activity. Treatment-related serious adverse events were lymphopenia (N = 21), bradycardia (N = 19), elevated transaminases (N = 9) and macular oedema (N = 9).Conclusions: The effectiveness and tolerability of fingolimod in everyday clinical practice are consistent with findings of previous phase III studies. Our study highlights the utility of fingolimod for the long-term management of patients with multiple sclerosis.

Published
2022
Full Text
View/download PDF

28. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Author

Sabathé, Camille, primary, Casey, Romain, additional, Vukusic, Sandra, additional, Leray, Emmanuelle, additional, Mathey, Guillaume, additional, De Sèze, Jérôme, additional, Ciron, Jonathan, additional, Wiertlewski, Sandrine, additional, Ruet, Aurélie, additional, Pelletier, Jean, additional, Zéphir, Hélène, additional, Michel, Laure, additional, Lebrun-Frenay, Christine, additional, Moisset, Xavier, additional, Thouvenot, Eric, additional, Camdessanché, Jean-Philippe, additional, Bakchine, Serge, additional, Stankoff, Bruno, additional, Al Khedr, Abdullatif, additional, Cabre, Philippe, additional, Maillart, Elisabeth, additional, Berger, Eric, additional, Heinzlef, Olivier, additional, Hankiewicz, Karolina, additional, Moreau, Thibault, additional, Gout, Olivier, additional, Bourre, Bertrand, additional, Wahab, Abir, additional, Labauge, Pierre, additional, Montcuquet, Alexis, additional, Defer, Gilles, additional, Maurousset, Aude, additional, Maubeuge, Nicolas, additional, Dimitri Boulos, Dalia, additional, Ben Nasr, Haïfa, additional, Nifle, Chantal, additional, Casez, Olivier, additional, Laplaud, David-Axel, additional, and Foucher, Yohann, additional

Published
2022
Full Text
View/download PDF

29. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Author

Roos, Izanne, Malpas, Charles, Leray, Emmanuelle, Casey, Romain, Horakova, Dana, Havrdova, Eva Kubala, Debouverie, Marc, Patti, Francesco, De Seze, Jerome, Izquierdo, Guillermo, Eichau, Sara, Edan, Gilles, Prat, Alexandre, Girard, Marc, Ozakbas, Serkan, Grammond, Pierre, Zephir, Helene, Ciron, Jonathan, Maillart, Elisabeth, Moreau, Thibault, Amato, Maria Pia, Labauge, Pierre, Alroughani, Raed, Buzzard, Katherine, Skibina, Olga, Terzi, Murat, Laplaud, David Axel, Berger, Eric, Grand'Maison, Francois, Lebrun-Frenay, Christine, Cartechini, Elisabetta, Boz, Cavit, Lechner-Scott, Jeannette, Clavelou, Pierre, Stankoff, Bruno, Prevost, Julie, Kappos, Ludwig, Pelletier, Jean, Shaygannejad, Vahid, Yamout, Bassem I, Khoury, Samia J, Gerlach, Oliver, Spitaleri, Daniele L A, Van Pesch, Vincent, Gout, Olivier, Turkoglu, Recai, Heinzlef, Olivier, Thouvenot, Eric, McCombe, Pamela Ann, Soysal, Aysun, Bourre, Bertrand, Slee, Mark, Castillo-Trivino, Tamara, Bakchine, Serge, Ampapa, Radek, Butler, Ernest Gerard, Wahab, Abir, Macdonell, Richard A, Aguera-Morales, Eduardo, Cabre, Philippe, Ben, Nasr Haifa, Van der Walt, Anneke, Laureys, Guy, Van Hijfte, Liesbeth, Ramo-Tello, Cristina M, Maubeuge, Nicolas, Hodgkinson, Suzanne, Sánchez-Menoyo, José Luis, Barnett, Michael H, Labeyrie, Celine, Vucic, Steve, Sidhom, Youssef, Gouider, Riadh, Csepany, Tunde, Sotoca, Javier, de Gans, Koen, Al-Asmi, Abdullah, Fragoso, Yara Dadalti, Vukusic, Sandra, Butzkueven, Helmut, Kalincik, Tomas, MSBase and OFSEP, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, University of Melbourne, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), Recherche sur les services et le management en santé (RSMS), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], CHU Pontchaillou [Rennes], Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, CIC Plurithématique de Nantes, Institut National de la Santé et de la Recherche Médicale (INSERM)-Ministère des Affaires sociales et de la Santé-Direction générale de l'offre de soins (DGOS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Unité de Recherche Clinique de la Côte d’Azur (URRIS UR2CA), Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Génomique Fonctionnelle (IGF), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)

Subjects
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Fingolimod Hydrochloride, Recurrence, [SDV]Life Sciences [q-bio], Natalizumab, Humans, Female, Neurology (clinical), Immunosuppressive Agents, Research Article, Retrospective Studies
Abstract

Objectives:To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy.Methods:This was a retrospective cohort study from two large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12-months were included in the analysis. The primary study outcome was annualised relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation.Results:14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for seven therapies. Annualised rates of relapse (ARR) started to increase 2-months after natalizumab cessation (month 2-4 ARR, 95% confidence interval): 0.47, 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89), and stabilised faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01-0.29). Magnitude of disease reactivation for other therapies was low, but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were higher relapse rate in the year before cessation, female sex, younger age and higher EDSS. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95%CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80).Conclusion:The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimised after stopping anti-trafficking therapies (natalizumab and fingolimod).Classification of evidence:This study provides class III that disease reactivation occurs within months of discontinuation of multiple sclerosis disease-modifying therapies. Risk of disease activity is reduced by commencement of a subsequent therapy.

Published
2022
Full Text
View/download PDF

31. Long-term efficacy of cognitive-behavioral approaches (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a randomized, parallel-group, multicenter, open-label, controlled trial versus standard care (S19.009)

Author

Heinzlef, Olivier, primary, Cassedanne, Fanny, additional, Barbot, Frederic, additional, Vaugier, Isabelle, additional, Blanchere, Marie, additional, Manchon, Eric, additional, Bensmail, Djamel, additional, and Gay, Marie Claire, additional

Published
2022
Full Text
View/download PDF

32. Efficacité à long terme des approches cognitives et comportementales (TCC) dans la gestion de la fatigue chez les patients atteints de sclérose en plaques récurrente-rémittente (SEP-RR) : un essai clinique randomisé (ECR), en groupes parallèles, multicentrique, ouvert et contrôlé par rapport aux soins standards

Author

Hamelin, Fanny, primary, Blanchere, Marie, additional, Barbot, Frédéric, additional, Vaugier, Isabelle, additional, Thomas, Sarah, additional, Manchon, Eric, additional, Bensmail, Djamel, additional, Heinzlef, Olivier, additional, and Gay, Marie-Claire, additional

Published
2022
Full Text
View/download PDF

34. sj-docx-1-msj-10.1177_13524585221139156 – Supplemental material for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Author

Sabathé, Camille, Casey, Romain, Vukusic, Sandra, Leray, Emmanuelle, Mathey, Guillaume, De Sèze, Jérôme, Ciron, Jonathan, Wiertlewski, Sandrine, Ruet, Aurélie, Pelletier, Jean, Zéphir, Hélène, Michel, Laure, Lebrun-Frenay, Christine, Moisset, Xavier, Thouvenot, Eric, Camdessanché, Jean-Philippe, Bakchine, Serge, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Maillart, Elisabeth, Berger, Eric, Heinzlef, Olivier, Hankiewicz, Karolina, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Montcuquet, Alexis, Defer, Gilles, Maurousset, Aude, Maubeuge, Nicolas, Dimitri Boulos, Dalia, Ben Nasr, Haïfa, Nifle, Chantal, Casez, Olivier, Laplaud, David-Axel, and Foucher, Yohann

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221139156 for Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system by Camille Sabathé, Romain Casey, Sandra Vukusic, Emmanuelle Leray, Guillaume Mathey, Jérôme De Sèze, Jonathan Ciron, Sandrine Wiertlewski, Aurélie Ruet, Jean Pelletier, Hélène Zéphir, Laure Michel, Christine Lebrun-Frenay, Xavier Moisset, Eric Thouvenot, Jean-Philippe Camdessanché, Serge Bakchine, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Elisabeth Maillart, Eric Berger, Olivier Heinzlef, Karolina Hankiewicz, Thibault Moreau, Olivier Gout, Bertrand Bourre, Abir Wahab, Pierre Labauge, Alexis Montcuquet, Gilles Defer, Aude Maurousset, Nicolas Maubeuge, Dalia Dimitri Boulos, Haïfa Ben Nasr, Chantal Nifle, Olivier Casez, David-Axel Laplaud and Yohann Foucher in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

36. Long-Term Effectiveness of a Cognitive Behavioral Therapy (CBT) in the Management of Fatigue in Patients with Relapsing Remitting Multiple Sclerosis (RRMS): A Multi-Centre, Randomised, Open-Label, Controlled Trial Versus Standard Care

Author

Gay, Marie-Claire, primary, Cassedanne, Fanny, additional, Barbot, Frédéric, additional, Vaugier, Isabelle, additional, Thomas, Sarah, additional, Manchon, Eric, additional, Bensmail, Djamel, additional, Blanchère, Marie, additional, and Heinzlef, Olivier, additional

Published
2022
Full Text
View/download PDF

37. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Author

Ziemssen, Tjalf, Bajenaru, Ovidiu A., Carrá, Adriana, de Klippel, Nina, de Sá, João C., Edland, Astrid, Frederiksen, Jette L., Heinzlef, Olivier, Karageorgiou, Klimentini E., Lander Delgado, Rafael H., Landtblom, Anne-Marie, Macías Islas, Miguel A., Tubridy, Niall, and Gilgun-Sherki, Yossi

Published
2014
Full Text
View/download PDF

39. Effect of Operator's Experience on Proficiency in Mechanical Thrombectomy: A Multicenter Study

Author

François Zhu, Wagih Ben Hassen, Nicolas Bricout, Basile Kerleroux, Kevin Janot, Benjamin Gory, René Anxionnat, Sébastien Richard, Adrien Marchal, Raphael Blanc, Michel Piotin, Arturo Consoli, Denis Trystram, Christine Rodriguez Regent, Jean-Philippe Desilles, David Weisenburger-Lile, Simon Escalard, Denis Herbreteau, Heloise Ifergan, Igor Lima Maldonado, Julien Labreuche, Hilde Henon, Olivier Naggara, Bertrand Lapergue, Grégoire Boulouis, Redjem Hocine, Ciccio Gabriele, Smajda Stanislas, Maier Benjamin, Mazighi Mikael, Obadia Mikael, Sabben Candice, Peres Roxanne, Corabianu Ovide, De Broucker Thomas, Smadja Didier, Alamowitch Sonia, Ille Olivier, Manchon Eric, Garcia Pierre-Yves, Taylor Guillaume, Ben Maacha Malek, Wang Adrien, Evrard Serge, Tchikviladze Maya, Ajili Nadia, Gorza Lucas, Buard Géraldine, Coskun Oguzhan, Di Maria Federico, Rodesh Georges, Zimatore Sergio, Leguen Morgan, Gratieux Julie, Pico Fernando, Rakotoharinandrasana Haja, Tassan Philippe, Poll Roxanna, Marinier Sylvie, Nighoghossian Norbert, Riva Roberto, Eker Omer, Turjman Francis, Derex Laurent, Cho Tae-Hee, Mechtouff Laura, Claire Lukaszewicz Anne, Philippeau Frédéric, Cakmak Serkan, Blanc-Lasserre Karine, Vallet Anne-Evelyne, Marnat Gaultier, Gariel Florent, Barreau Xavier, Berge Jérôme, Menegon Patrice, Sibon Igor, Liegey Sebastien, Olindo Stéphane, Renou Pauline, Sagnier Sharmila, Poli Mathilde, Debruxelles Sabrina, Pangon Nicolas, Bourcier Romain, Detraz Lili, Daumas-Duport Benjamin, Alexandre Pierre-Louis, Roy Monica, Lenoble Cédric, L’allinec Vincent, Girot Jean-Baptiste, Desal Hubert, Bracard Serge, Braun Marc, Derelle Anne-Laure, Tonnelet Romain, Liao Liang, Muszynski Patricio, Schmitt Emmanuelle, Planel Sophie, Humbertjean Lisa, Mione Gioia, Lacour Jean-Christophe, Riou-Comte Nolwenn, Audibert Gérard, Voicu Marcela, Alb Ionel, Reitter Marie, Brezeanu Madalina, Masson Agnès, Tabarna Adriana, Podar Ioana, Macian-Montoro Francisco, Saleme Suzanna, Mounayer Charbel, Rouchaud Aymeric, Costalat Vincent, Arquizan Caroline, Dargazanli Cyril, Gascou Grégory, Lefèvre Pierre-Henri, Derraz Imad, Riquelme Carlos, Gaillard Nicolas, Mourand Isabelle, Corti Lucas, Francois Eugene, Vannier Stéphane, Ferre Jean-Christophe, Raoult Helene, Ronziere Thomas, Lassale Maria, Paya Christophe, Gauvrit Jean-Yves, Tracol Clément, Langnier-Lemercier Sophie, Samson Yves, Rosso Charlotte, Leger Anne, Deltour Sandrine, Clarencon Frederic, Shotar Eimad, Spelle Laurent, Denier Christian, Chassin Olivier, Chalumeau Vanessa, Caroff Jildaz, Venditti Laura, Turc Guillaume, Seners Pierre, Domigo Valérie, Lamy Catherine, Birchenall Julia, Isabel Clothilde, Viguier Alain, Cognard Christophe, Christine Januel Anne, Olivot Jean-Marc, Raposo Nicolas, Bonneville Fabrice, François Albucher Jean, Calviere Lionel, Touze Emmanuel, Barbier Charlotte, Schneckenburger Romain, Boulanger Marion, Cogez Julien, Guettier Sophie, Timsit Serge, Gentric Jean-Christophe, Ognard Julien, Mathias Merrien Francois, Ozkul Wermester Ozlem, Massardier Evelyne, Papagiannaki Chrysanthi, Bourdain Frédéric, Patricia Bernady, Lagoarde-Segot Laurent, Cailliez Hélène, Veunac Louis, Higue David, Wolff Valérie, Pop Raoul, Beaujeux Rémi, Mihoc Dan-Sorin, Manisor Monica, Le Bras Anthony, Evain Sarah, Le Guen Arnaud, Richter Sebastian, Hubrecht Regis, Demasles Stéphanie, Barroso Bruno, Zuber Mathieu, Farhat Wassim, Alias Quentin, Lun François, Stenvenoot Delphine, Heinzlef Olivier, Godon Hardy Sylvie, Bohotin Valentin, and Grimaud Jérôme

Subjects
medicine.medical_specialty, Standard of care, Time Factors, Neuroradiologist, 030204 cardiovascular system & hematology, Brain Ischemia, 03 medical and health sciences, 0302 clinical medicine, Operator (computer programming), Medicine, Humans, Registries, Thrombectomy, Advanced and Specialized Nursing, Surgeons, business.industry, Cerebral infarction, Endovascular Procedures, Cerebral Infarction, medicine.disease, Mechanical thrombectomy, Stroke, Multicenter study, Ischemic stroke, Reperfusion, Physical therapy, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery
Abstract

Background and Purpose: We aimed to evaluate among trained interventional neuroradiologist, whether increasing individual experience was associated with an improvement in mechanical thrombectomy (MT) procedural performance metrics. Methods: Individual MT procedural data from 5 centers of the Endovascular Treatment in Ischemic Stroke registry and 2 additional high-volume stroke centers were pooled. Operator experience was defined for each operator as a continuous variable, cumulating the number of MT procedures performed since January 2015, as MT became standard of care or, if later than this date, since the operator started performing mechanical thrombectomies in autonomy. We tested the associations between operator’s experience and procedural metrics. Results: A total of 4516 procedures were included, performed by 36 operators at 7 distinct centers, with a median of 97.5 endovascular treatment procedures per operator (interquartile range, 57–170.2) over the study period. Higher operator’s experience, analyzed as a continuous variable, was associated with a significantly shorter procedural duration (β estimate, −3.98 [95% CI, −5.1 to −2.8]; P P =0.013). Conclusions: In trained interventional neuroradiologists, increasing experience in MT is associated with significantly shorter procedural duration and better reperfusion rates, with a theoretical ceiling effect observed after around 100 procedures. These results may inform future training and practice guidelines to set minimal experience standards before autonomization, and to set-up operators’ recertification processes tailored to individual case volume and prior experience.

Published
2021

40. Improving Health of People With Multiple Sclerosis From a Multicenter Randomized Controlled Study in Parallel Groups: Preliminary Results on the Efficacy of a Mindfulness Intervention and Intention Implementation Associated With a Physical Activity Program

Author

Torkhani, Eya, primary, Dematte, Emilie, additional, Slawinski, Jean, additional, Csillik, Antonia, additional, Gay, Marie-Claire, additional, Bensmaïl, Djamel, additional, Heinzlef, Olivier, additional, and de Marco, Giovanni, additional

Published
2021
Full Text
View/download PDF

41. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Author

Januel, Edouard, primary, De Seze, Jérôme, additional, Vermersch, Patrick, additional, Maillart, Elisabeth, additional, Bourre, Bertrand, additional, Pique, Julie, additional, Moisset, Xavier, additional, Bensa, Caroline, additional, Maarouf, Adil, additional, Pelletier, Jean, additional, Vukusic, Sandra, additional, Audoin, Bertrand, additional, Louapre, Céline, additional, Beltran, Stéphane, additional, Berger, Eric, additional, Bigaut, Kevin, additional, Derache, Nathalie, additional, Gassama, Salimata, additional, Heinzlef, Olivier, additional, Kremer, Laurent, additional, Kerschen, Philippe, additional, Maurousset, Aude, additional, Ricigliano, Vito A G, additional, Garcia, Pierre-Yves, additional, and Labauge, Pierre, additional

Published
2021
Full Text
View/download PDF

42. Comparative effectiveness of dimethyl fumarate in multiple sclerosis

Author

Bosco‐Lévy, Pauline, primary, Debouverie, Marc, additional, Brochet, Bruno, additional, Guillemin, Francis, additional, Louapre, Céline, additional, Maillart, Elisabeth, additional, Heinzlef, Olivier, additional, Lignot, Séverine, additional, Diez, Pauline, additional, Abouelfath, Abdelilah, additional, Lassalle, Régis, additional, Blin, Patrick, additional, and Droz‐Perroteau, Cécile, additional

Published
2021
Full Text
View/download PDF

43. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts

Author

Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Eva Kubala Havrdova, Alroughani, Raed, Ayuso, Guillermo Izquierdo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, Mccombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Walt, Anneke, Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele Litterio A., Vucic, Ostoja, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurelie, Seze, Jerome, Maillart, Elisabeth, Zephir, Helene, Labauge, Pierre, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanche, Jean-Philippe, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Celine, Nifle, Chantal, Laplaud, David, Koch-Henriksen, Nils, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Pfleger, Claudia Christina, Rasmussen, Peter Vestergaard, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas

Published
2021

44. Additional file 1 of Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Abstract

Additional file 1: Algorithm for the identification of multiple sclerosis relapses.

Published
2021
Full Text
View/download PDF

45. Additional file 2 of Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data

Author

Thurin, Nicolas H., Bosco-Levy, Pauline, Blin, Patrick, Rouyer, Magali, Jové, Jérémy, Lamarque, Stéphanie, Lignot, Séverine, Lassalle, Régis, Abouelfath, Abdelilah, Bignon, Emmanuelle, Diez, Pauline, Gross-Goupil, Marine, Soulié, Michel, Roumiguié, Mathieu, Le Moulec, Sylvestre, Debouverie, Marc, Brochet, Bruno, Guillemin, Francis, Louapre, Céline, Maillart, Elisabeth, Heinzlef, Olivier, Moore, Nicholas, and Droz-Perroteau, Cécile

Abstract

Additional file 2: Algorithm performance indicators before setting adjustment resulting from expert inputs.

Published
2021
Full Text
View/download PDF

46. sj-pdf-1-msj-10.1177_1352458520981300 – Supplemental material for Determinants of therapeutic lag in multiple sclerosis

Author

Izanne Roos, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, J William L Brown, Horakova, Dana, Havrdova, Eva Kubala, Debouverie, Marc, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Edan, Gilles, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ciron, Jonathan, Ruet, Aurélie, Ozakbas, Serkan, Seze, Jérôme De, Louapre, Céline, Zephir, Hélène, Sá, Maria José, Sola, Patrizia, Ferraro, Diana, Labauge, Pierre, Defer, Gilles, Bergamaschi, Roberto, Lebrun-Frenay, Christine, Boz, Cavit, Cartechini, Elisabetta, Moreau, Thibault, Laplaud, David, Lechner-Scott, Jeannette, Francois Grand’Maison, Gerlach, Oliver, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo, Pesch, Vincent Van, Wijmeersch, Bart Van, Spitaleri, Daniele LA, Soysal, Aysun, Berger, Eric, Prevost, Julie, Aguera-Morales, Eduardo, McCombe, Pamela, Triviño, Tamara Castillo, Clavelou, Pierre, Pelletier, Jean, Turkoglu, Recai, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Sidhom, Youssef, Gouider, Riadh, Tunde Csepany, Bourre, Bertrand, Abdullatif Al Khedr, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Jean-Philippe Camdessanche, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Coles, Alasdair, Malpas, Charles B, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-msj-10.1177_1352458520981300 for Determinants of therapeutic lag in multiple sclerosis by Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva Kubala Havrdova, Marc Debouverie, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Gilles Edan, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Jonathan Ciron, Aurélie Ruet, Serkan Ozakbas, Jérôme De Seze, Céline Louapre, Hélène Zephir, Maria José Sá, Patrizia Sola, Diana Ferraro, Pierre Labauge, Gilles Defer, Roberto Bergamaschi, Christine Lebrun-Frenay, Cavit Boz, Elisabetta Cartechini, Thibault Moreau, David Laplaud, Jeannette Lechner-Scott, Francois Grand’Maison, Oliver Gerlach, Murat Terzi, Franco Granella, Raed Alroughani, Gerardo Iuliano, Vincent Van Pesch, Bart Van Wijmeersch, Daniele LA Spitaleri, Aysun Soysal, Eric Berger, Julie Prevost, Eduardo Aguera-Morales, Pamela McCombe, Tamara Castillo Triviño, Pierre Clavelou, Jean Pelletier, Recai Turkoglu, Bruno Stankoff, Olivier Gout, Eric Thouvenot, Olivier Heinzlef, Youssef Sidhom, Riadh Gouider, Tunde Csepany, Bertrand Bourre, Abdullatif Al Khedr, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean-Philippe Camdessanche, Aude Maurousset, Ivania Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle, Alasdair Coles, Charles B Malpas, Sandra Vukusic, Helmut Butzkueven and Tomas Kalincik in Multiple Sclerosis Journal

Published
2021
Full Text
View/download PDF

47. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, Magyari, Melinda, Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, and Magyari, Melinda

Abstract

Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. Methods: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. Results: The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. Conclusion: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.

Published
2021

49. Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study

Author

Cohen, Mikael, Maillart, Elisabeth, Tourbah, Ayman, De Sèze, Jérôme, Vukusic, Sandra, Brassat, David, Anne, Olivier, Wiertlewski, Sandrine, Camu, William, Courtois, Sylvie, Ruet, Aurélie, Debouverie, Marc, Le Page, Emmanuelle, Casez, Olivier, Heinzlef, Olivier, Stankoff, Bruno, Bourre, Bertrand, Castelnovo, Giovanni, Rico, Audrey, Berger, Eric, Camdessanche, Jean-Philippe, Defer, Gilles, Clavelou, Pierre, Al Khedr, Abdullatif, Zephir, Hélène, Fromont, Agnès, Papeix, Caroline, Brochet, Bruno, Pelletier, Jean, and Lebrun, Christine

Published
2014
Full Text
View/download PDF

50. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

Author

Gavoille, Antoine, Rollot, Fabien, Casey, Romain, Debouverie, Marc, Le Page, Emmanuelle, Ciron, Jonathan, De Seze, Jerome, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Helene, Papeix, Caroline, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Laplaud, David Axel, Berger, Eric, Stankoff, Bruno, Clavelou, Pierre, Thouvenot, Eric, Heinzlef, Olivier, Pelletier, Jean, Al Khedr, Abdullatif, Casez, Olivier, Bourre, Bertrand, Cabre, Philippe, Wahab, Abir, Magy, Laurent, Camdessanche, Jean-Philippe, Maurousset, Aude, Moulin, Solène, Ben, Nasr Haifa, Boulos, Dalia Dimitri, Hankiewicz, Karolina, Neau, Jean-Philippe, Pottier, Corinne, Nifle, Chantal, Rabilloud, Muriel, Subtil, Fabien, and Vukusic, Sandra

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results